Biocon Ltd reported a mixed set of Q4 FY26 results, where underlying resilience in its biosimilars portfolio cushioned the impact of a steep profit decline driven largely by a high base effect and one-off items from the previous year.
The company posted a consolidated net profit of ₹126 crore, down 63.5% year-on-year from ₹345 crore in Q4 FY25. While the headline decline appears sharp, management and underlying segment trends suggest the fall was more accounting-driven than operational weakness.
Revenue from operations inched up 2.3% YoY to ₹4,517 crore from ₹4,417 crore, indicating steady but muted top-line expansion in a challenging comparison period.
Margin pressure but less severe than feared
EBITDA declined 5.4% to ₹1,020 crore from ₹1,078 crore, while margins contracted to 22.6% from 24.4%. However, the compression was lower than market expectations, suggesting that operational discipline helped absorb part of the pressure.
Analysts noted that the quarter was shaped by two distortions: a strong base in Q4 FY25 driven by elevated generic lenalidomide sales, and an exceptional item in the current quarter that weighed on profitability.
Biosimilars drive steady growth
The biosimilars division remained the standout performer, growing 12% year-on-year. The segment benefited from expanding market traction and new product launches, reinforcing its position as the core growth engine for the company.
In contrast, the CRDMO business operated through Syngene International delivered a modest 2% YoY growth, limiting overall momentum across the integrated portfolio.
Integration strategy and global positioning
The company highlighted continued progress on its structural transformation, having integrated its biosimilars, generics formulations, and API businesses into a unified biopharma platform. This integration is aimed at improving operational efficiency, strengthening the balance sheet, and expanding global commercial reach.
Management emphasised that the combined entity now carries stronger leverage metrics and a broader international footprint, positioning it for long-term profitability enhancement.
Leadership transition ahead
The quarter also comes at a time of leadership transition. Founder Kiran Mazumdar-Shaw is expected to hand over executive responsibilities to Claire Mazumdar, marking a significant generational shift in the company’s governance structure while retaining strategic continuity.
Kiran Mazumdar-Shaw noted that FY26 closed on a strong operational footing despite geopolitical uncertainty, highlighting margin expansion (adjusted for one-offs) and 13% YoY operating revenue growth excluding last year’s exceptional lenalidomide impact.
Dividend announcement
The board recommended a final dividend of ₹0.50 per share (10% of face value) for FY26, reflecting a steady return commitment despite earnings volatility.
Outlook
While headline profits were under pressure, the quarter underscored a stabilising core business, with biosimilars continuing to anchor growth. The focus now shifts toward scaling global launches, improving profitability mix, and leveraging the integrated structure for sustained value creation.